(Q37919869)

English

Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?

scientific article published on 19 September 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

1 reference

Europe PubMed Central

Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand? (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

0 references

eradication of infectious diseases

1 reference

based on heuristic

inferred from title

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Eric Van Den Neste

1

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Rémi Letestu

2

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Thérèse Aurran-Schleinitz

3

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Loïc Ysebaert

4

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Pierre Feugier

5

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Stéphane Leprêtre

6

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Caroline Dartigeas

7

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

publication date

19 September 2011

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

53

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

362-370

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Minimal residual disease assessment in chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

State-of-the-art treatment of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Alemtuzumab maintenance may safely prolong chemotherapy-free intervals in chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL).

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Rituximab dose-escalation trial in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Repeated rituximab maintenance courses in fludarabine-failed young patients with chronic lymphocytic leukaemia responding to FAND chemotherapy

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Treatment of younger patients with chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Monoclonal antibodies for the treatment of hematologic malignancies: schedule and maintenance therapy

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Rituximab-associated infections

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia: a report of three cases and review of the literature.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Antigenic modulation and rituximab resistance

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Modulation of CD20 antigen expression after rituximab treatment: a retrospective study in patients with chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Improvement of rituximab efficiency in chronic lymphocytic leukemia by CpG-mediated upregulation of CD20 expression independently of PU.1.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608450

21 January 2018

Identifiers

10.3109/10428194.2011.608450

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37919869&oldid=2117828475"